地拉罗司医保后的价格是多少？

(Enrig) What is the price after medical insurance? Let's take a look. Deferasirox (Enriga) was developed by Novartis and is currently the only oral iron chelator. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In 2010, Deferasirox (Enriga) was approved for marketing in China and is approved for the treatment of chronic iron overload caused by frequent blood transfusions in beta-thalassemia patients aged 2 years and above, and for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndrome aged 10 years and above.

According to Medical Companion Travel, Deferasirox (Enrige) has not yet been officially included in medical insurance and cannot be reimbursed by medical insurance. It is a drug paid for by the patient at his own expense. The price of Deferasirox (Enrego) is relatively high after it is launched in China, with a box costing about $2,000. For an ordinary person weighing 60kg, the cost of taking deferasirox for a month is more than about $24,000. It can be seen that it is difficult for ordinary families to accept this price and cannot afford it.

Fortunately, there are also foreign versions for everyone to choose from. Novartis of Switzerland imported deferasirox (Enrego) into India. The specification is 400mg*30 tablets/box, and the price is about $700. The specification of Deferasirox (Enrego) produced by Indian pharmaceutical factory is 500*30 tablets/box, and the price is about 500$. Due to the fluctuation of exchange rate, the price will be different. Please consult the medical companion for the specific price.

Thalassemia, also known as thalassemia, blood transfusion is the main treatment for thalassemia major and thalassemia intermedia. Long-term blood transfusion can easily lead to secondary iron overload. Iron overload refers to the pathological phenomenon of excessive iron deposition in human tissues and organs, leading to cell damage and organ dysfunction. Iron overload can cause damage to cardiovascular, endocrine, liver, kidney, nervous system, etc., leading to various diseases and serious harm. Iron chelators can effectively increase iron excretion, reduce iron content in the body and its pathological deposition in various organs. (Enrig) ​​is currently the only effective drug for the treatment of iron overload.

Recommended related hot articles: /newsDetail/75902.html